BioAegis and Prenosis partner for inflammatory disease therapies
BioAegis Therapeutics has entered a strategic partnership with Prenosis to advance AI-driven precision medicine for inflammatory diseases. The collaboration will…
22 Apr 2026
Health Canada approves Biocon’s two denosumab biosimilars
Biocon has received a Notice of Compliance from Health Canada for Bosaya (denosumab) and Vevzuo (denosumab), both biosimilars referencing Prolia and Xgeva, respectively. The approval covers Bosaya in a 60mg/ml…
21 Apr 2026
Eli Lilly doubles down on in vivo with $7bn Kelonia buyout
Eli Lilly has agreed to acquire Massachusetts-based gene therapy developer, Kelonia Therapeutics, for up to $7bn – marking the pharma’s second foray into the in vivo space this year. Through…
21 Apr 2026
Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy
Pfizer and Astellas have received the US Food and Drug Administration (FDA) acceptance for priority review of their supplemental biologics licence application (sBLA) for perioperative Padcev (enfortumab vedotin-ejfv) combined with…
21 Apr 2026
Asahi Kasei acquires German company Aicuris
Asahi Kasei has completed its acquisition of Aicuris Anti-infective Cures, a German biopharmaceutical company. The move comes after Asahi Kasei signed a definitive agreement to acquire all issued shares of…
20 Apr 2026
British patients risking “fake” weight loss drugs, despite safety concerns, survey says
A survey by digital healthcare provider Zava has revealed that British patients are increasingly turning to potentially unregulated weight loss drugs as demand surges and global medicine prices climb. Of…
20 Apr 2026
Boehringer Ingelheim launches AI centre in London
Boehringer Ingelheim has launched a new artificial intelligence (AI) and machine learning (ML) centre in London, representing the company’s latest move to drive improved patient outcomes through the technologies’ application.…